{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T18:13:27Z","timestamp":1775067207584,"version":"3.50.1"},"reference-count":10,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archivos de la Sociedad Espa\u00f1ola de Oftalmolog\u00eda"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.oftal.2019.04.013","type":"journal-article","created":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T08:54:49Z","timestamp":1559811289000},"page":"396-399","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Tratamiento con ciclosporina al 0,1% (Ikervis\u00ae) en conjuntivitis corticodependiente asociada a dupilumab"],"prefix":"10.1016","volume":"94","author":[{"given":"J.","family":"Roca-Gin\u00e9s","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Rahhal-Ortu\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Torres-Navarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Rodr\u00edguez-Serna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.\u00c1.","family":"Navarro-Mira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.oftal.2019.04.013_bib0055","volume":"Vol. 1","author":"Bolognia","year":"2018"},{"key":"10.1016\/j.oftal.2019.04.013_bib0060","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1172\/JCI57416","article-title":"Epidermal barrier dysfunction and cutaneous sensitization in atopic diseases","volume":"122","author":"Kubo","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.oftal.2019.04.013_bib0065","doi-asserted-by":"crossref","first-page":"100","DOI":"10.2340\/00015555-0207","article-title":"Systemic treatment of severe atopic eczema: a systematic review","volume":"87","author":"Schmitt","year":"2007","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.oftal.2019.04.013_bib0070","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","article-title":"Dupilumab in persistent asthma with elevated eosinophil levels","volume":"368","author":"Wenzel","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.oftal.2019.04.013_bib0075","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.oftal.2019.04.013_bib0080","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to- severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): A 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.oftal.2019.04.013_bib0085","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/j.jaip.2018.01.034","article-title":"Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab-clinical characteristics and treatment","volume":"6","author":"Wollenberg","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.oftal.2019.04.013_bib0090","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1001\/jamadermatol.2018.2690","article-title":"Risk Factors for Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis","volume":"154","author":"Treister","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.oftal.2019.04.013_bib0095","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ajoc.2017.06.017","article-title":"Cicatricial ectropion in a patient treated with dupilumab","volume":"7","author":"Barnes","year":"2017","journal-title":"Am J Ophthalmol Case Rep"},{"key":"10.1016\/j.oftal.2019.04.013_bib0100","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/CE.S133661","article-title":"Dupilumab: An evidence-based review of its potential in the treatment of atopic dermatitis","volume":"13","author":"Eshtiaghi","year":"2018","journal-title":"Core Evid"}],"container-title":["Archivos de la Sociedad Espa\u00f1ola de Oftalmolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365669119301571?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365669119301571?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T23:42:56Z","timestamp":1759794176000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0365669119301571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":10,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0365669119301571"],"URL":"https:\/\/doi.org\/10.1016\/j.oftal.2019.04.013","relation":{},"ISSN":["0365-6691"],"issn-type":[{"value":"0365-6691","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tratamiento con ciclosporina al 0,1% (Ikervis\u00ae) en conjuntivitis corticodependiente asociada a dupilumab","name":"articletitle","label":"Article Title"},{"value":"Archivos de la Sociedad Espa\u00f1ola de Oftalmolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oftal.2019.04.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Sociedad Espa\u00f1ola de Oftalmolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}